Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 12/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21491800 | 0.87 | KLKB1 (0.42) | KLKB1NAMPTPPARDGLSTRPV1 | |
| Trifluoroacetic Acid SCHEMBL21492407 | 0.85 | PPARD (0.42) | KLKB1NAMPTPPARDGLSEGLN1 | |
| Trifluoroacetic Acid SCHEMBL30056789 | 0.85 | PPARD (0.42) | KLKB1NAMPTPPARDGLSEGLN1 | |
| SCHEMBL24400371 | 0.85 | HDAC3 (0.42) | KLKB1NAMPTPPARDGLS | |
| SCHEMBL30744352 | 0.85 | HDAC3 (0.42) | KLKB1NAMPTPPARDGLS | |
| SCHEMBL22501639 | 0.83 | TRPV1 (0.52) | NAMPTGLSTRPV1SCN5ASCN9A | |
| SCHEMBL28529563 | 0.83 | KLKB1 (0.39) | KLKB1NAMPTPPARDGLSTRPV1 | |
| SCHEMBL21491519 | 0.83 | GLS (0.38) | KLKB1PPARDGLS | |
| SCHEMBL21492287 | 0.81 | GAA (0.47) | KLKB1NAMPT | |
| SCHEMBL21492711 | 0.81 | PPARD (0.42) | NAMPTPPARDGLSTRPV1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | KLKB1 630/4885NAMPT 14/4885PPARD 159/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | KLKB1 630/4885NAMPT 14/4885PPARD 159/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | KLKB1 630/4885NAMPT 14/4885PPARD 159/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | KLKB1 630/4885NAMPT 14/4885PPARD 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.